Position in ANVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$10,416
+$9,330 QoQ
Shares Held
5,600
+1683.4% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#41
of 61 holders
Holding Since
Dec 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANVS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ROYAL BANK OF CANADA holds $2,116,200,724 across 427 Biotechnology names. ANVS ranks #281 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
6,182,479 | $490,208,754 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
980,259 | $486,924,048 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
875,859 | $263,659,830 | |
| 4 | INCY |
Incyte Corp
|
1,132,050 | $128,329,182 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
174,515 | $108,817,078 | |
| 6 | MRNA |
Moderna, Inc.
|
944,457 | $66,140,319 | |
| 7 | INSM |
INSMED Inc
|
416,487 | $44,405,840 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
545,761 | $42,716,712 |
All Filings in ANVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,416 | 5,600 | Shares | Defined | 2026-08-14 | |
| 2025-12-31 | $1,086 | 314 | Shares | Defined | 2026-02-17 | |
| 2025-06-30 | $3,393 | 1,564 | Shares | Defined | 2025-11-21 | |
| 2024-06-30 | $414 | 72 | Shares | Defined | 2024-11-06 | |
| 2024-03-31 | $47 | 4 | Shares | Defined | 2024-11-05 | |
| 2023-12-31 | $748 | 40 | Shares | Defined | 2024-02-14 | |
| 2023-09-30 | $379 | 40 | Shares | Defined | 2023-11-14 | |
| 2023-06-30 | $1,857 | 130 | Shares | Defined | 2023-08-14 | |
| 2022-09-30 | $54 | 4 | Shares | Defined | 2022-11-14 | |
| 2021-12-31 | $52 | 3 | Shares | Defined | 2022-02-14 | |
| No filing history on record for this holder in this stock. | ||||||